• Home
  • About Us
    • Meet Our Team
    • Vision, Mission and Core Values
    • Trusted Partners
    • Giving Back
    • In the News
    • Awards
    • Careers
  • For Patients
    • Study Opportunities
    • Clinical Trial Opportunities
    • Sign Up to Participate
    • Types of Research
    • Find Us in the Community
    • Frequently Asked Questions
    • Testimonials
    • How We Use Your Information
    • Newsletters
  • For Researchers
    • Patient/Caregiver Panels
    • Pricing
    • Proposal Requests
    • Frequently Asked Questions
    • Industry Conferences
    • Diseases
      • Hemophilia
      • Multiple Sclerosis
      • Breast Cancer
      • Diabetes
      • Multiple Myeloma
      • Epilepsy
      • Non-Small Cell Lung Cancer
      • HIV
  • Referral Program
  • Blog
    • Patient Blog
    • Business Blog
  • Sign In
  • Case Studies
    • The Long and Winding Road to Care
    • Health Literacy Initiative’s PSA
    • Patient Perspectives on Clinical Trial Participation
    • Patient Journeys and Insights for Oncology and Rare Diseases
    • Market Access: A Patient Perspective
    • The Impact of Rare Diseases on Patients and Caregivers
    • The Role of Patient Advocacy Groups
    • Zebras Do Exist: The Diagnostic Odyssey of Rare Disease Patients
    • Patient Insights on Telehealth: A Case Study
    • Hearing is Believing: Reducing Barriers to Amplify the Patient Voice

Rare Patient Voice

Helping Patients with Rare Diseases Voice Their Opinions

  • Home
  • About Us
    • Meet Our Team
    • Vision, Mission and Core Values
    • Trusted Partners
    • Giving Back
    • In the News
    • Awards
    • Careers
  • For Patients
    • Study Opportunities
    • Clinical Trial Opportunities
    • Sign Up to Participate
    • Types of Research
    • Find Us in the Community
    • Frequently Asked Questions
    • Testimonials
    • How We Use Your Information
    • Newsletters
  • For Researchers
    • Patient/Caregiver Panels
    • Pricing
    • Proposal Requests
    • Frequently Asked Questions
    • Industry Conferences
    • Diseases
      • Hemophilia
      • Multiple Sclerosis
      • Breast Cancer
      • Diabetes
      • Multiple Myeloma
      • Epilepsy
      • Non-Small Cell Lung Cancer
      • HIV
  • Referral Program
  • Blog
    • Patient Blog
    • Business Blog
  • Sign In
  • Case Studies
    • The Long and Winding Road to Care
    • Health Literacy Initiative’s PSA
    • Patient Perspectives on Clinical Trial Participation
    • Patient Journeys and Insights for Oncology and Rare Diseases
    • Market Access: A Patient Perspective
    • The Impact of Rare Diseases on Patients and Caregivers
    • The Role of Patient Advocacy Groups
    • Zebras Do Exist: The Diagnostic Odyssey of Rare Disease Patients
    • Patient Insights on Telehealth: A Case Study
    • Hearing is Believing: Reducing Barriers to Amplify the Patient Voice

Helping patients and caregivers share their voices

How do we determine project feasibility?

May 11, 2019 Wes Michael

Feasibility is a key issue for market research panels. What is feasibility, what are we talking about?

Feasibility is, how many of a certain patient type can we actually get to complete your survey. Not how many do we have, not how many respond, but how many can complete. This is what you need to know – can we complete the project as designed, do you need additional partners to complete it, do you need to lower your client’s expectations?

Three things make up feasibility: total available, response rate, and incidence rate.

1.    How many do we have to be invited? This is the total number of those appropriate patients or caregivers we have in the panel. This is not a secret, we post our panel sizes, and share them explicitly in our proposals. But that is not the number that will complete the study! Some clients misinterpret this as the number we can get for a study! No, it is not that! This is just the starting point! You can’t get everyone to participate!

2.    How many will respond to the invitation to the study? That is what we call response rate. This we have to estimate. For our non-cancer panels, it is about 50%, that is half of the people we send an email to about a project will express interest in participating. For our cancer panels, it is closer to 20%. We can estimate this fairly accurately based on our history with the panels. But this is not the final answer! Not everyone who is interested in taking part will qualify!

3.    Which leads to the final component, what we call the incidence rate or IR. What is that? The incidence rate is what percent of those who are interested that will qualify. We do not determine that! It is dependent on the screener. We depend on the client to give us their best estimate of the incidence rate. We are happy to give our best guess once we see the screener, but we won’t really know until we launch the study. If you think the screener is not very restrictive, we may estimate the incidence rate at 70%. We don’t like to go higher than that. But if there are restrictive criteria – the patient has to use a certain drug, or have been diagnosed within a year, or be in an attitudinal segment – the incidence rate goes a lot lower.

We had a client recently who misunderstood incidence rate – they say we had promised an IR of 50%. No! We can’t promise an incidence rate! It is based on the screening criteria. We can only report what the incidence rate turns out to be! In their case it was only 6%.

What we can do, pretty quickly after a study launches, is report on the incidence rate. With a quant study, our client sees this, they have to let us know. But with qual, we see this. Then we need to see why it is low – is there a certain question that people are terminating on? Can the client loosen the specifications on that question? For example, if the screener wants patients diagnosed in the past year, and that is kicking most people out, maybe they could loosen that to allow patients diagnosed in the past two years.

Sometimes when the IR rate is lower than expected, the initial idea is that we need to just find more people. But think about it. If the IR is 6%, and you need another 100 completes, we would need to get 1,667 more to respond to get the 100 completes, and we’d need 3,334 available to get to those 1,667 at a 50% response rate. So, you’d need to get a LOT more people. Usually that is not the answer, or it is only part of the answer, when the IR is low.

We list all three of these components in our bids: total available, response rate, and incidence rate. We determine the first two, but the third, IR, is determined by the screener. We can only report what it is, and how you might change it. Please ask if you ever have any questions! We don’t want you disappointed because the feasibility has been misunderstood!

Filed Under: Business

Latest Blog Posts

  • Weekly Warrior: Meet Harper
  • Weekly Warrior: Meet Eric
  • Meet Our Team: Chris Cooper, Senior Project Manager
  • Weekly Warriors: Meet Morgan and Maddison
  • Weekly Warriors: Meet Sebastian and Christopher

Check Out Our YouTube Channel!

https://youtu.be/cfjkqh5Ykp0

Read Our Newsletter

Read our Newsletter
What’s New at Rare Patient Voice?

Rare Patient Voice

711 Hampton Lane
Towson, Maryland 21286
ContactUs@RarePatientVoice.com
(443) 986-1949


Visit our international site, rarepatientvoice.global


Careers


For Patients

  • Learn about us
  • Vision, Mission and Core Values
  • Sign up to participate
  • Find us in the community
  • Read our blog for patients
  • Privacy Policy

For Related Groups

  • What is the Rare Patient Voice referral program?
  • Are you a researcher?
  • Read our blog for businesses

   Instagram TikTok

     
     

Rare Patient Voice, LLC, Market Research, Towson, MD

Rare Patient Voice, LLC, Market Research, Towson, MD

©2023. Rare Patient Voice. All Rights
Reserved. Privacy Policy | Sitemap

©2023 . All Rights Reserved.

Copyright © 2023 · Genesis Framework · WordPress · Log in

Search Our Website

We use cookies to ensure the best experience with Rare Patient Voice. By clicking “Accept”, you agree to our privacy policy.
Privacy Policy   |    Cookies    |    Accept
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT